Reaction
Injection Site Paraesthesia reporting signals
As of the last recalculation, Injection Site Paraesthesia appears in 1,488 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is BOTULINUM TOXIN TYPE A (PRR 17.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Botulinum Toxin Type A | 15 | 17.1 | 17.1 |
| Tirzepatide | 165 | 15.9 | 16.0 |
| Asfotase Alfa | 7 | 9.8 | 9.8 |
| Onabotulinumtoxina | 47 | 8.8 | 8.8 |
| Dulaglutide | 53 | 8.6 | 8.6 |
| Fremanezumab-Vfrm | 7 | 8.6 | 8.6 |
| Naltrexone | 18 | 8.3 | 8.3 |
| Galcanezumab-Gnlm | 18 | 8.1 | 8.1 |
| Inclisiran | 4 | 7.0 | 7.0 |
| Glatiramer Acetate | 28 | 6.7 | 6.7 |
| Bimekizumab | 10 | 6.6 | 6.6 |
| Evolocumab | 58 | 5.2 | 5.2 |
| Interferon Beta-1B | 7 | 5.1 | 5.1 |
| Ofatumumab | 12 | 5.1 | 5.1 |
| Ixekizumab | 13 | 4.9 | 5.0 |
| Etanercept | 175 | 4.5 | 4.5 |
| Erenumab-Aooe | 15 | 3.8 | 3.8 |
| Exenatide | 14 | 3.7 | 3.7 |
| Abaloparatide | 7 | 3.3 | 3.3 |
| Somatropin | 16 | 3.1 | 3.1 |
| Dupilumab | 87 | 2.6 | 2.6 |